生产企业：Cocrystal Pharma, Inc.
First oral direct-acting antiviral in development for the prevention and treatment of norovirus infection; Cocrystal Pharma's lead candidate, granted FDA Fast Track designation.
First oral direct-acting antiviral in development for the prevention and treatment of norovirus infection; Cocrystal Pharma's lead candidate, granted FDA Fast Track designation.
Oral, direct-acting 3CL protease inhibitor designed to target the highly conserved region of the 3CL protease across all known norovirus strains (including GII.4 and the re-emerging GII.17 variants) as well as all coronaviruses.
Treatment and prophylaxis of norovirus infection
共 1 项相关疾病
